Recommended
More Related Content
Similar to Common Protocol Template (CPT) Initiative - How was CPT Developed and What Does it Look Like?
Similar to Common Protocol Template (CPT) Initiative - How was CPT Developed and What Does it Look Like? (20)
More from TransCelerate
More from TransCelerate (14)
Recently uploaded
Recently uploaded (20)
Common Protocol Template (CPT) Initiative - How was CPT Developed and What Does it Look Like?
- 1. December 2017 How was CPT Developed and What Does it Look Like?
- 2. Copyright ©2017 TransCelerate BioPharma Inc., All rights reserved. * Confidential - NOT FOR DISTRIBUTION * How was the CPT Developed? Structure and Content Structure – Level 1 and 2 Headings •Main focus - Streamlined structure for logical flow •Review of structure (Table of Contents) of anonymized member company templates •Input from SCRS (Society for Clinical Research Sites) Site Advocacy Group Section Content •Identification of common wording in Core Backbone •Review of GCP, ICH, and EU requirements •Review of content from member company templates
- 3. Copyright ©2017 TransCelerate BioPharma Inc., All rights reserved. * Confidential - NOT FOR DISTRIBUTION * eProtocol Advisory Committee “…to inform the development of a common human readable and electronic protocol template and provide a forum for key stakeholders to inform future direction and provide know-how (Committee Charter)” “EMA has not agreed to take up a position on the Advisory Committee…..Happy to provide comments on any draft templates…” Other Advisors or Influencers FDA 18-Mar-2016: “Today we’re announcing a draft clinical trial protocol template developed by the Food and Drug Administration (FDA) and National Institutes of Health (NIH) that should help with that. …..We are aware of other efforts in this area, including one undertaken by TransCelerate Biopharma Inc. (TransCelerate), which has issued a common protocol template intended to be the basis for a forthcoming electronic protocol. Although our initial target audiences differ, we plan to collaborate with groups like TransCelerate to help ensure consistency for the medical product development community.” How was the CPT Developed? Initial Advisory Committee Engagement
- 4. Copyright ©2017 TransCelerate BioPharma Inc., All rights reserved. * Confidential - NOT FOR DISTRIBUTION * Focus on sites (investigators/study staff) to have access to protocol information. 1. CPT Structure and Content will provide value to Investigators, site staff, IRBs, regulators The same information is located in the same place and means the same thing across Sponsors Locked text (Level 1 and 2 Headings) is not to be modified or removed. “Not Applicable” is inserted if a section is not applicable. 2. Specific information to evaluate the ability to conduct a protocol, e.g. does the site have the patient population. 3. Refer to primary sources of information (e.g. Investigator Brochure) instead of duplicating information in the protocol. 4. Model sections and text located in Appendices to be accessible, but will not impact the flow of the core protocol-specific information How was the CPT Developed? Final Template
- 5. Copyright ©2017 TransCelerate BioPharma Inc., All rights reserved. * Confidential - NOT FOR DISTRIBUTION * What Does the CPT Look Like? The Model Libraries Core Protocol Backbone Common Level 1 & 2 Headings Common text Used across all phases Focus on investigators Healthy Volunteer Patient Therapeutic Area Libraries (various) Appendices Non-study specific info, items triggered by event Implementation Toolkit Materials Core streamlined, focused on site needs Appendices to apply as applicable Libraries group and store point and click content used to populate the template Endpoint Definitions modeled for TAs/indications A sustainable Governance Model is in development Common Protocol Template and Guidance Governance Model Common Text can be used “as is”- relevant across study types
- 6. Copyright ©2017 TransCelerate BioPharma Inc., All rights reserved. * Confidential - NOT FOR DISTRIBUTION * Basic Word Edition • A document based template for use across phases and study types • Use as-is or modify current format template to reflect CPT content • Initial Public Release: December 2015 Technology Enabled Edition • An MSWord-based template with add-ins • Automation to leverage “point and click” protocol text, • Capture of protocol-level metadata to facilitate content reuse and extraction • Initial Public Release: June 2016 For Microsoft Windows-based usage, not compatible with Apple iOS. What Does the CPT Look Like? CPT Editions
- 7. Copyright ©2017 TransCelerate BioPharma Inc., All rights reserved. * Confidential - NOT FOR DISTRIBUTION * What Does the CPT Look Like? Tech-Enabled Edition CPT Panel A. Filter: select participant and therapeutic area libraries B. Folder: navigate to all libraries C. Instructional Text Box Panel: section- specific guidance D. Additional Content Box: (D1) Navigate to library text. Click once to preview content (D2); click twice to add to protocol. Add-Ins E. Add Variables: Reuse content F. Example Text Tools: Convert example text to protocol text, remove example text G. About: Link to guides for use & implementation, releases H. Libraries/Instructions/Content: Pop out instructional text box and Toggle CPT Panel I. Manage Variables: Add custom variables J. Data Tools: Export variables and text to XML; import variables J A,B C D1 D2 E F G H I J
- 8. Thank you
Editor's Notes
- Legally approved 8-Apr-2017 Content development was a logical, thoughtful approach, acknowledging that not one member company protocol was preferred over another, as all meet the GCP and ICH requirements. The main focus was to streamline the content to allow for consistency across the pharma industry. The structure of the Level 1 and 2 headers are intended to be used/adopted for use without changes. If a section does not apply, retaining the heading and inserting “NA” or “Not applicable” will allow a consistent protocol structure for multiple sponsors across industry. The impact will be that the Investigators, study staff and IRBs will be able to locate the same information in the same place and meaning the same thing across multiple protocols. The Level 3 headers and lower level headers can be adjusted as needed . GCP and ICH guidance was reviewed as the initial step for creating common core content. A comparison of the content in the member companies protocols was completed as part of the development of the common core content. With intended focus on sites (investigators/coordinators), the core includes content to (1) evaluate whether a site has the patients/facilities/time to conduct a protocol, and (2) the specific information needed to conduct the protocol. Other items have been placed in appendices (including governance-related text) where they are accessible but do not impact the flow of the core information. The core content guidance provided with the template also suggests that the reader refer to the primary sources of information (e.g. IB), where possible, rather than bulk repetition in the protocol. This organization in the document has the added advantage of streamlining the protocol overall. This streamlining is expected to allow more efficient use of the protocol.
- Legally approved 8-Apr-2017 TransCelerate sponsored formation of the Electronic Protocol Advisory Committee to inform the initial development of a common human readable and electronic protocol template and provide a forum for key stakeholders to inform future direction and provide know-how. This Advisory Committee was designed to be similar to, but lighter version of, the Coalition for Accelerating Standards and Therapies (CFAST) structure. Input has been received from some eProtocol Advisory Committee members, and additional input is being requested. The intent is to promote “energy” around the idea of an eProtocol platform, and to drive alignment around end to end traceability, automation, and reuse. Through this Advisory Committee, TransCelerate workstreams will continue to get advice, and access to external “know-how.” The groups across the bottom of this slide are not directly involved in this Advisory Committee, but their outputs have been considered in developing the CPT, and their influence is considered via the other Advisory Committee channels. Tufts was consulted specifically regarding CPT project scope, priorities, and deliverables. The SPIRIT checklist was a key reference and influenced the creation of the text-based structure and content. A consultative meeting was held with the Budapest Working Group, with additional input pending. It is envisioned that additional advisors, such as HL7 and IHE, will be pursued as we move toward development of the machine-readable template
- Legally approved 8-Apr-2017 Content development was a logical, thoughtful approach, acknowledging that not one member company protocol was preferred over another, as all meet the GCP and ICH requirements. The main focus was to streamline the content to allow for consistency across the pharma industry. The structure of the Level 1 and 2 headers are intended to be used/adopted for use without changes. If a section does not apply, retaining the heading and inserting “NA” or “Not applicable” will allow a consistent protocol structure for multiple sponsors across industry. The impact will be that the Investigators, study staff and IRBs will be able to locate the same information in the same place and meaning the same thing across multiple protocols. The Level 3 headers and lower level headers can be adjusted as needed . GCP and ICH guidance was reviewed as the initial step for creating common core content. A comparison of the content in the member companies protocols was completed as part of the development of the common core content. With intended focus on sites (investigators/coordinators), the core includes content to (1) evaluate whether a site has the patients/facilities/time to conduct a protocol, and (2) the specific information needed to conduct the protocol. Other items have been placed in appendices (including governance-related text) where they are accessible but do not impact the flow of the core information. The core content guidance provided with the template also suggests that the reader refer to the primary sources of information (e.g. IB), where possible, rather than bulk repetition in the protocol. This organization in the document has the added advantage of streamlining the protocol overall. This streamlining is expected to allow more efficient use of the protocol.
- Legally approved 8-Apr-2017 Backbone contains the protocol information common to all phases, populations, and therapeutic areas. The core is streamlined and focused on the sites’ needs. Libraries group and store content to be inserted into the core backbone and contain specific information related to therapy, country, study population (e.g., patient, healthy volunteer) needs. Appendices provide additional information that can be accessed when needed (e.g., abbreviations, company specific content). Appendices are omitted if not applicable. Highlight that the template is for all TAs. Additional content available for some specific therapeutic areas.
- Legally approved 8-Apr-2017
- Legally approved 8-Apr-2017